EZETIMIBE AND SIMVASTATIN

Post-LOESM

ezetimibe and simvastatin

Ichnos Glenmark Innovation

ANDAORALTABLET

Approved

Jun 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

EZETIMIBE AND SIMVASTATIN (ezetimibe and simvastatin) by Ichnos Glenmark Innovation is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction, stroke and 5 more indications. First approved in 2019.

Drug data last refreshed 18h ago

Mechanism of Action

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Class:

Dietary Cholesterol Absorption Inhibitor

Indications (8)

total mortality by reducing risk of coronary heart disease death non-fatal myocardial infarction

Worked on EZETIMIBE AND SIMVASTATIN at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT00817843Phase 4Completed

The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study

Started Apr 2009

100 enrolled

Metabolic Syndrome

NCT00317993Phase 4Completed

LDL Receptor Under Ezetimibe and Simvastatin

Started Apr 2004

60 enrolled

Healthy Men